Amicus (FOLD) Stock Forecast & Price Target

Compare

1,002 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

FOLD Analyst Ratings

Strong Buy

6 Buy

1 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Amicus

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

FOLD Stock 12 Month Forecast

Average Price Target

$17.00

▲(176.87%Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Amicus in the last 3 months. The average price target is $17.00 with a high forecast of $22.00 and a low forecast of $13.00. The average price target represents a 176.87% change from the last price of $6.14.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","14":"$14","23":"$23","9.5":"$9.5","18.5":"$18.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$22.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,9.5,14,18.5,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.16,7.378461538461538,8.596923076923076,9.815384615384616,11.033846153846154,12.252307692307692,13.470769230769232,14.68923076923077,15.907692307692308,17.126153846153848,18.344615384615384,19.563076923076924,20.78153846153846,{"y":22,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.16,6.993846153846154,7.827692307692308,8.661538461538461,9.495384615384616,10.329230769230769,11.163076923076922,11.996923076923077,12.830769230769231,13.664615384615384,14.498461538461537,15.332307692307692,16.166153846153847,{"y":17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.16,6.686153846153847,7.212307692307693,7.7384615384615385,8.264615384615386,8.790769230769232,9.316923076923077,9.843076923076923,10.36923076923077,10.895384615384616,11.421538461538463,11.947692307692307,12.473846153846154,{"y":13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.43,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.8,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.2,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.61,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.66,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.47,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.96,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.42,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.58,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.49,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.95,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.68,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.16,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$22.00

Average Price Target$17.00

Lowest Price Target$13.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

Hold

14.01%

Upside

Reiterated

05/17/25

Amicus Therapeutics shows promising revenue growth and strategic developments. However, challenges with profitability, high leverage, and current bearish technical indicators are concerns. The positive outlook from the earnings call and strategic corporate events provide optimism for future growth, balancing the current financial and technical challenges.

Dennis DingJefferies

Jefferies

$16

Buy

160.59%

Upside

Reiterated

06/06/25

Analysts' Top Healthcare Picks: Amicus (FOLD), Inspire Medical Systems (INSP)

Tiago FauthWells Fargo

Wells Fargo

$17→$13

Buy

111.73%

Upside

Reiterated

05/02/25

Amicus Therapeutics (FOLD) PT Lowered to $13 at Wells FargoWells Fargo lowered its price target on Amicus Therapeutics (NASDAQ: FOLD) to $13.00 (from $17.00) while maintaining a Overweight rating.

Eliana MerleUBS

UBS

$21→$22

Buy

258.31%

Upside

Reiterated

05/02/25

Amicus price target raised to $22 from $21 at UBSAmicus price target raised to $22 from $21 at UBS

Ritu BaralTD Cowen

TD Cowen

$20

Buy

225.73%

Upside

Reiterated

05/01/25

Amicus's Strategic Positioning and Growth Potential Justify Buy Rating Despite Revenue Misses

Gil BlumNeedham

Needham

―

Hold

―

Reiterated

05/01/25

Amicus (FOLD) Gets a Hold from Needham

Joseph SchwartzLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

04/30/25

Amicus Positioned for Growth with Strategic Licensing and Promising FSGS Treatment

Tazeen AhmadBank of America Securities

Bank of America Securities

$14

Buy

128.01%

Upside

Reiterated

04/17/25

Bank of America Securities Reaffirms Their Buy Rating on Amicus (FOLD)

Maxwell SkorMorgan Stanley

Morgan Stanley

$12

Hold

95.44%

Upside

Initiated

03/06/25

Balanced Outlook on Amicus Therapeutics Amid Growth Ambitions and Market Challenges

Anupam RamaJ.P. Morgan

J.P. Morgan

$17→$16

Buy

160.59%

Upside

Reiterated

02/28/25

Amicus Therapeutics (FOLD) PT Lowered to $16 at JPMorganJPMorgan analyst Anupam Rama lowered the price target on Amicus Therapeutics (NASDAQ: FOLD) to $16.00 (from $17.00) while maintaining a Overweight rating.

Debjit ChattopadhyayGuggenheim

Guggenheim

$15

Buy

144.30%

Upside

Reiterated

02/20/25

We maintain our BUY rating and PT of $15/share based on our 8-year DCF-based, sum-of- the-parts analysis driven by: beta of 1.1; terminal growth rate of 1%; risk premium of 4.2%; estimated WACC of 7.6% (prior 9%, updated based on revised cost of equity); and tax rate of 15% beginning in FY 2025.

Kristen KluskaCantor Fitzgerald

Cantor Fitzgerald

$21

Buy

242.02%

Upside

Reiterated

01/15/25

Cantor Fitzgerald Sticks to Their Buy Rating for Amicus (FOLD)

Salveen RichterGoldman Sachs

Goldman Sachs

$14

Hold

128.01%

Upside

Reiterated

01/14/25

Goldman Sachs reiterates Neutral Rating on Amicus Therapeutics (FOLD)Goldman Sachs analyst Salveen Richter reiterated a Neutral rating and $14.00 price target on Amicus Therapeutics (NASDAQ: FOLD)

Dae Gon HaStifel Nicolaus

Stifel Nicolaus

$20

Buy

225.73%

Upside

Reiterated

07/08/24

Amicus (FOLD) Gets a Buy from Stifel Nicolaus

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

Hold

14.01%

Upside

Reiterated

05/17/25

Dennis DingJefferies

Jefferies

$16

Buy

160.59%

Upside

Reiterated

06/06/25

Analysts' Top Healthcare Picks: Amicus (FOLD), Inspire Medical Systems (INSP)

Tiago FauthWells Fargo

Wells Fargo

$17→$13

Buy

111.73%

Upside

Reiterated

05/02/25

Amicus Therapeutics (FOLD) PT Lowered to $13 at Wells FargoWells Fargo lowered its price target on Amicus Therapeutics (NASDAQ: FOLD) to $13.00 (from $17.00) while maintaining a Overweight rating.

Eliana MerleUBS

UBS

$21→$22

Buy

258.31%

Upside

Reiterated

05/02/25

Amicus price target raised to $22 from $21 at UBSAmicus price target raised to $22 from $21 at UBS

Ritu BaralTD Cowen

TD Cowen

$20

Buy

225.73%

Upside

Reiterated

05/01/25

Amicus's Strategic Positioning and Growth Potential Justify Buy Rating Despite Revenue Misses

Gil BlumNeedham

Needham

―

Hold

―

Reiterated

05/01/25

Amicus (FOLD) Gets a Hold from Needham

Joseph SchwartzLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

04/30/25

Amicus Positioned for Growth with Strategic Licensing and Promising FSGS Treatment

Tazeen AhmadBank of America Securities

Bank of America Securities

$14

Buy

128.01%

Upside

Reiterated

04/17/25

Bank of America Securities Reaffirms Their Buy Rating on Amicus (FOLD)

Maxwell SkorMorgan Stanley

Morgan Stanley

$12

Hold

95.44%

Upside

Initiated

03/06/25

Balanced Outlook on Amicus Therapeutics Amid Growth Ambitions and Market Challenges

Anupam RamaJ.P. Morgan

J.P. Morgan

$17→$16

Buy

160.59%

Upside

Reiterated

02/28/25

Debjit ChattopadhyayGuggenheim

Guggenheim

$15

Buy

144.30%

Upside

Reiterated

02/20/25

Kristen KluskaCantor Fitzgerald

Cantor Fitzgerald

$21

Buy

242.02%

Upside

Reiterated

01/15/25

Cantor Fitzgerald Sticks to Their Buy Rating for Amicus (FOLD)

Salveen RichterGoldman Sachs

Goldman Sachs

$14

Hold

128.01%

Upside

Reiterated

01/14/25

Goldman Sachs reiterates Neutral Rating on Amicus Therapeutics (FOLD)Goldman Sachs analyst Salveen Richter reiterated a Neutral rating and $14.00 price target on Amicus Therapeutics (NASDAQ: FOLD)

Dae Gon HaStifel Nicolaus

Stifel Nicolaus

$20

Buy

225.73%

Upside

Reiterated

07/08/24

Amicus (FOLD) Gets a Buy from Stifel Nicolaus

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Amicus

1 Month

xxx

Success Rate

9/14 ratings generated profit

Average Return

+2.46%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 64.29% of your transactions generating a profit, with an average return of +2.46% per trade.

3 Months

xxx

Success Rate

9/14 ratings generated profit

Average Return

+8.38%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +8.38% per trade.

1 Year

Debjit ChattopadhyayGuggenheim

Success Rate

7/14 ratings generated profit

Average Return

+17.14%

reiterated a buy rating 4 months ago

Copying Debjit Chattopadhyay's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +17.14% per trade.

2 Years

xxx

Success Rate

4/17 ratings generated profit

Average Return

-18.75%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 23.53% of your transactions generating a profit, with an average return of -18.75% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

FOLD Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, FOLD has received 7 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. FOLD average Analyst price target in the past 3 months is 17.00.

Each month's total comprises the sum of three months' worth of ratings.

FOLD Financial Forecast

FOLD Earnings Forecast

Next quarter’s earnings estimate for FOLD is -$0.11 with a range of -$0.20 to -$0.03. The previous quarter’s EPS was -$0.07. FOLD beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year FOLD has Outperformed its overall industry.

FOLD Sales Forecast

Next quarter’s sales forecast for FOLD is $147.04M with a range of $137.77M to $157.60M. The previous quarter’s sales results were $125.25M. FOLD beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year FOLD has Outperformed its overall industry.

FOLD Stock Forecast FAQ

What is FOLD’s average 12-month price target, according to analysts?

Based on analyst ratings, Amicus Therapeutics’s 12-month average price target is 17.00.

What is FOLD’s upside potential, based on the analysts’ average price target?

Amicus Therapeutics has 176.87% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is FOLD a Buy, Sell or Hold?

Amicus Therapeutics has a consensus rating of Strong Buy which is based on 6 buy ratings, 1 hold ratings and 0 sell ratings.

What is Amicus Therapeutics’s price target?

The average price target for Amicus Therapeutics is 17.00. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $22.00 ,the lowest forecast is $13.00. The average price target represents 176.87% Increase from the current price of $6.14.

What do analysts say about Amicus Therapeutics?

Amicus Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of FOLD?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Amicus (FOLD) Stock Forecast & Price Target

FOLD Analyst Ratings

FOLD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Amicus

FOLD Analyst Recommendation Trends

FOLD Financial Forecast

FOLD Earnings Forecast

FOLD Sales Forecast

FOLD Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts